ee025268-74c1-48ec-aa7f-74f0c8ae126220210205104354637wseamdt@crossref.orgMDT DepositWSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE1109-951810.37394/23208http://wseas.org/wseas/cms.action?id=40112720202720201710.37394/23208.2020.17http://wseas.org/wseas/cms.action?id=23181Increased Resistance of Fluoroquinolones among H. pylori isolates from Patients with Gastroduodenal Diseases in JordanLuayAbu-QatousehFaculty of Pharmacy and Medical Sciences, University of Petra, Amman, JORDANEyadMallahFaculty of Pharmacy and Medical Sciences, University of Petra, Amman, JORDANMonaBustamiFaculty of Pharmacy and Medical Sciences, University of Petra, Amman, JORDANEmadAlkhateebFaculty of Pharmacy and Medical Sciences, University of Petra, Amman, JORDANRecently, Helicobacter pylori has been connected to more than 80% of chronic active gastritis and other gastroduodenal diseases worldwide. Treatment of H. pylori is routinely dependent on the use of multiple antimicrobial agents however, recent data showed the emergence of resistance among clinical strains especially against metronidazole and clarithromycin. This study was conducted to investigate the rate of resistance to different antibiotics that are routinely used in the first line and second line therapies including ciprofloxacin and levofloxacin, tetracycline, amoxicillin, clarithromycin and metronidazole among H. pylori strains isolated from patients with gastroduodenal diseases in Jordan. Both antral and corpus mucosal biopsies from the stomach of patients with positive results of H. pylori stool antigen and urease breath tests were used for the isolation of H. pylori on selective culture media. The standard agar diffusion method was performed to determine the sensitivity of H. pylori clinical isolates against ciprofloxacin and levofloxacin according to CLSI. Among 62 H. pylori clinical strains isolated from gastric biopsies, 21% and 11% were resistant to levofloxacin and ciprofloxacin respectively. Resistance to metronidazole and clarithromycin was found in 90% and 11% respectively. No resistance was observed against amoxicillin, tetracycline and gemifloxacin. The following MIC90 (mg/L) of resistant strains results were obtained at neutral pH 7.3, 64 for metronidazole, 2 for clarithromycin, 2 for ciprofloxacin and 1 for levofloxacin. The present study reported the emergence of increased resistance of fluoroquinolones among H. pylori clinical isolates in Jordan. Concern should be taken into consideration when triple and quadruple therapy regimens are applied for the management of H. pylori infections in our region624202062420207681https://www.wseas.org/multimedia/journals/biology/2020/a205108-079.pdf10.37394/23208.2020.17.10https://www.wseas.org/multimedia/journals/biology/2020/a205108-079.pdf10.1111/j.1582-4934.2005.tb00508.xM. Hayama, Y. Kawakami, Y. Kaneko, K. Sano, H. Ota. Helicobacter pylori infection increases cell kinetics in human gastric epithelial cells without adhering to proliferating cells. J Cell Mol Med, vol 9, 2005, pp. 746-747. 10.1111/apa.13724Raj, Priya, John F. Thompson, and Debra H. Pan. Helicobacter pylori serology testing is a useful diagnostic screening tool for symptomatic inner city children. Acta Paediatrica, vol 106, 2017, pp. 470-477. 10.1111/j.1523-5378.1996.tb00041.xT. Shimizu, T. Akamatsu, A. Sugiyama H. Ota. Helicobacter pylori and the surface mucous gel layer of the human stomach. Helicobacter, vol 1, 1996, pp. 207-218. 10.1016/s0140-6736(16)32404-7Lanas, Angel, and Francis KL Chan."Peptic ulcer disease. The Lancet, vol 390, 2017, pp 613-624.10.1053/j.gastro.2009.07.060C.Y. Wu, K.N. Kuo, M.S. Wu, Y.J. Chen, C.B. Wang, J.T. Lin. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology, vol 137, 2009, pp. 1641-1648.L. M. Brown. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev, vol 22 , 2000, pp. 283-297.J.G Kusters, A. an Vliet, E. Kuipers. Pathogenesis of Helicobacter pylori Infection. Clin Microbiol Rev, vol 19, 2006, pp. 449-490.10.1007/s00535-019-01639-wTake, S., Mizuno, M., Ishiki, K., Kusumoto, C., Imada, T., Hamada, F & Okada, H. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. Journal of Gastroenterology, vol 55, 2020, pp281-288. 10.1099/0022-1317-51-8-705K. Wolle, A. Leodolter, P. Malfertheiner, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol, vol, 51, 2002, pp.705–709.10.1001/archinte.161.9.1217M. Osato, R. Reddy, S. Reddy et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med, vol 161, 2001, pp.1217–1220. 10.1016/s1590-8658(00)80352-7A. Pilotto, M. Rassu, G. Leandro, et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis, vol 32, 2000, pp. 763–768.10.1111/j.1572-0241.2003.t01-1-07288.xL . Laine, R. Hunt, H. El-Zimaity et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicentre, North American trial. Am J Gastroenterol, vol 98, 2003, pp.562-567. 10.3823/794L. Abu-Qatouseh, M. Abu-Sini, A. M. A Mayyas, R. Darwish, T. Aburjai, I. Sabri. Molecular characterization and antibiotic susceptibility profiles of Helicobacter pylori isolated from patients with Gastrodeudenal diseases in Jordan. International arab Journal of antimicrobial agents, vol 6, 2017, pp. 1-8. J. Crowe, Sheila E. Helicobacter pylori infection.New England Journal of Medicinevol 380, no. 12, 2019, pp 1158-1165. 10.1111/j.1440-1746.2009.06139.xT. S. Chen, J.C. Luo, F.Y. Chang. Prevalence of Helicobacter pylori infection in duodenal ulcer and gastro-duodenal ulcer diseases in Taiwan. J Gastroenterol Hepatol, vol 25, 2010, pp. 919-92210.1097/00005176-200406001-00683H.Y. Lin, C.K. Chuang, H.C. Lee, N.C. Chiu, S.P. Lin, C.Y. Yeung A .seroepidemiologic study of Helicobacter pylori and hepatitis A virus infection in primary school students in Taipei. J Microbiol Immunol Infect, vol 38, 2005, pp. 176-182Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing CLSI (2010) M100–S20, Table 2L M07.10.1016/s0399-8320(09)72692-2H. Loghmari, F. Bdioui, W. Bouhlel, W. Melki, O. Hellara, N. Ben Chaabane, et al. Clarithromycin versus metronidazole in first-line Helicobacter pylori eradication. Prospective randomized study of 85 Tunisian adults. Tunis Med, vol 90, 2012, pp. 31-35. 10.1111/j.1440-1746.2009.05829.xW.L. Chang, B.S. Sheu, H.C. Cheng, Y.J. Yang, H.B. Yang, J.J. Wu Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan J Gastroenterol Hepatol, vol 24, 2009, pp. 1230-1235. 10.5897/ajb2010.000-3015N. Buta, N . Tanih, R. Ndip. Increasing trend of metronidazole resistance in the treatment of Helicobacter pylori infection: A global challenge. Afr J Biotechnol, 9(2010), pp. 1115-1121.10.1007/s12275-011-1170-6AT Abadi, T .Taghvaei, AM. Mobarez, BM. Carpenter, DS. Merrell. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol, vol 49, 2011, pp. 987-993.10.3823/789A.F Diab, DF. Hasan, SS. Nassar. Prevalence of Helicobacter pylori resistance to clarithromycin determined by 23S ribosomal RNA analysis in Jordan. International arab journal of antimicrobial agents, vol 6, 2016, pp. 1-5. 10.1111/j.1523-5378.2009.00655.xK.H. Hung, B.S. Sheu, W.L. Chang, H.M. Wu, C.C. Liu, J.J. Wu Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a university hospital in Southern Taiwan. Helicobacter, vol 14, 2009, pp. 61-65. 10.1128/aac.01131-10J.M. Liou, C.Y. Chang, W.H. Sheng, Y.C. Wang, M.J. Chen, Y.C. Lee, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother, vol 55, 2011, pp. 1123-1129.10.1093/jac/dkr410A. Cuadrado-Lavin, J.R. Salcines-Caviedes, M.F. Carrascosa, P. Mellado, I. Monteagudo, J. Llorca, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain.J Antimicrob Chemother, vol 67, 2012, pp. 170-173.10.1046/j.1365-2036.2000.00795.xHigh prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther, vol 14, 2000, pp. 901-910.10.3109/1061186x.2016.1171326Verma, Anurag, Juhi Dubey, Rahul Rama Hegde, Vaibhav Rastogi, and J. K. Pandit. Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems. Journal of drug targeting, vol 24, 2016, pp. 897-915.